このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.

The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.

調査の概要

詳細な説明

This study involves fasted and post-prandial components.

Fasted Study:

Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.

There will be a 4-week washout period during the two Treatment Periods.

Post-prandial study:

Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.

研究の種類

介入

入学 (予想される)

36

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Ontario
      • Guelph、Ontario、カナダ、N1G 0B4
        • Nutrasource Diagnostics Inc.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Be an adult between the ages of 18 and 70;
  • Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
  • Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
  • Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
  • Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
  • Have a Body Mass Index (BMI) less than 35.0
  • Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.

Exclusion Criteria:

  • Be younger than 18 years of age or older than 70 years of age;
  • Be an adult pre- or peri-menopausal female;
  • Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
  • Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
  • Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
  • Have high blood pressure [greater than 140/100]
  • Have a Body Mass Index (BMI) equal to or greater than 35.0
  • Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
  • Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
  • Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
  • Consume more than two (2) fish meals on a weekly basis
  • Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
  • Anticipate or have planned surgery during the course of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:1 (Dietary Supplement - Fish Oil)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
実験的:2 (Placebo)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Triglyceride [TG]
時間枠:0 and 4 weeks
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
0 and 4 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Glucose
時間枠:0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Insulin
時間枠:0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Total cholesterol [TC]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-density lipoprotein [HDL]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Low-density lipoprotein [LDL]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Very low-density lipoprotein [VLDL]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Lipoprotein A
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Intermediate-density lipoprotein [IDL]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Remnant Lipoproteins
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-sensitivity C-Reactive Protein [hs-CRP]
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Homocysteine
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Essential Fatty Acid Profile
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein B
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein A-1
時間枠:0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Alison Duncan, Ph.D., R.D.、University of Guelph

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2012年9月1日

一次修了 (実際)

2013年12月1日

研究の完了 (実際)

2014年2月1日

試験登録日

最初に提出

2012年9月10日

QC基準を満たした最初の提出物

2012年9月18日

最初の投稿 (見積もり)

2012年9月21日

学習記録の更新

投稿された最後の更新 (見積もり)

2014年2月7日

QC基準を満たした最後の更新が送信されました

2014年2月6日

最終確認日

2014年2月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する